Combinations comprising a VEGF receptor inhibitor and a penetration enhancer

Details for Australian Patent Application No. 2006291526 (hide)

Owner Novartis AG

Inventors Billich, Andreas; Stutz, Anton

Agent Davies Collison Cave

Pub. Number AU-B-2006291526

PCT Pub. Number WO2007/031265

Priority 0518671.3 13.09.05 GB; 0518672.1 13.09.05 GB

Filing date 12 September 2006

Wipo publication date 22 March 2007

Acceptance publication date 29 July 2010

International Classifications

A61K 31/505 (2006.01) - Pyrimidines

A61K 9/70 (2006.01) Medicinal preparations characterised by special physical form - Web, sheet or filament bases

A61K 31/44 (2006.01) - Non-condensed pyridines

A61K 31/501 (2006.01) - not condensed and containing further heterocyclic rings

A61K 31/506 (2006.01) - not condensed and containing further heterocyclic rings

A61K 31/519 (2006.01) - ortho- or peri-condensed with heterocyclic rings

A61K 31/538 (2006.01)

A61P 17/00 (2006.01) Drugs for dermatological disorders

A61P 17/06 (2006.01) Drugs for dermatological disorders

A61P 17/10 (2006.01) Drugs for dermatological disorders

Event Publications

3 April 2008 PCT application entered the National Phase

  PCT publication WO2007/031265 Priority application(s): WO2007/031265

29 July 2010 Application Accepted

  Published as AU-B-2006291526

25 November 2010 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2006291527-Conjugates of hydroxyalkyl starch and an active substance, prepared by chemical ligation via thiazolidine

2006291524-4-substituted pyrrolidin-2-ones and their use